Thymic Carcinoma: Current Staging Does Not Predict Prognosis  by Blumberg, David et al.
THYMIC CARCINOMA: CURRENT STAGING DOES NOT PREDICT PROGNOSIS
David Blumberg, MD
Michael E. Burt, MD, PhD†
Manjit S. Bains, MD
Robert J. Downey, MD
Nael Martini, MD
Valerie Rusch, MD
Robert J. Ginsberg, MD
Background: Thymic carcinomas are currently staged by Masaoka classifi-
cation, a staging system for thymomas. We retrospectively evaluated
surgical patients with thymic carcinoma to determine prognostic factors
and to evaluate the usefulness of Masaoka staging in this disease. Methods:
Our computerized tumor registry yielded 118 patients with thymoma.
Review of pathologic material revealed 43 cases of thymic carcinoma.
Collection of data was by review of hospital and physician charts and
telephone contact with patients. Analysis of prognostic factors was per-
formed in patients undergoing complete resection by the method of
Kaplan-Meier and Cox proportional hazards regression. Results: Between
1949 and 1993, 43 patients underwent surgery for thymic carcinoma.
Overall survival was 65% at 5 years and 35% at 10 years. Overall recurrence
was 65% at 5 years and 75% at 10 years. On univariate analysis, survival
was not dependent on age, sex, tumor size, or Masaoka stage but was
dependent on innominate vessel invasion. By multivariate analysis, survival
was dependent only on innominate vessel invasion. Conclusions: Patients
with thymic carcinoma have a high rate of recurrence. Tumor invasion of
the innominate vessels is associated with a particularly poor prognosis.
Although Masaoka staging is useful in staging patients with thymoma, it
does not appear to predict outcome for patients with thymic carcinoma.
(J Thorac Cardiovasc Surg 1998;115:303-9)
Although all thymomas are derived from the epi-thelial cells of the thymus, they represent a
diverse group of tumors with varied histologic find-
ings and biologic behavior. Histologic subtypes in-
clude predominantly lymphocytic, predominantly
epithelial, mixed lymphoepithelial, or spindle cell
thymomas, and thymic carcinomas. Compared with
other histologic subtypes, thymic carcinomas have
malignant cytologic findings1-3 and a clinical course
characterized by early and frequent metastasis and
poor survival.4-7 Studies to define prognostic vari-
ables or to test efficacy of treatment modalities for
patients with thymic carcinoma, however, have been
limited by the rarity of this tumor. As a result,
thymic carcinomas are currently staged and treated
by the same guidelines used for thymomas, despite
having a more aggressive histologic appearance and
clinical course.
In our recent review of 118 patients with thy-
moma, we reported 43 patients with thymic carcino-
mas seen over a 45-year period, representing one of
the largest single institutional experiences.8 Similar
to other reports, patients with thymic carcinoma
typically had advanced disease and had higher re-
currence rates and worse survival compared with
most thymomas. Because patients with thymic car-
cinoma have a worse prognosis compared with
patients with thymoma, we performed a multivariate
analysis to determine unique prognostic factors for
patients undergoing complete resection of thymic
carcinoma at Memorial Hospital.
Patients and methods
As previously reported, 118 patients with thymoma
were surgically treated at Memorial Hospital from 1949 to
1993.8 Forty-three of these patients were histologically
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proven to have thymic carcinomas by review of micro-
scopic sections by one pathologist (Dr. Juan Rosai). The
criteria for diagnosis of thymic carcinoma was an epithe-
lial cell thymic tumor with clear-cut cytologic features of
malignancy. Thymic carcinomas included tumors defined
as type II malignant thymomas, as described by Rosai and
colleagues,9, 10 and well-differentiated thymic carcinomas,
as defined by Kirchner, Schalke, Marx, and Mu¨ller-Herme-
link.11 Data were collected from medical charts on all 43
patients and follow-up was performed by review of physi-
cians office charts and contact of patients by telephone.
Analysis of prognostic factors of patients who had com-
plete resection was performed by the method of Kaplan
and Meier12 and by log rank analysis.13 Significance was
defined as p value less than 0.05.
Results
Patient demographics. Median age of patients
was 50 years (range 19 to 72). There were 27 men
and 16 women. Thirty-eight patients (88%) were
symptomatic at presentation with cough (n 5 14),
dyspnea (n 5 12), chest pain (n 5 10), superior vena
caval syndrome (n 5 4), myasthenia gravis (n 5 10),
red cell aplasia (n 5 3), and hypogammaglobuline-
mia (n 5 1).
Clinicopathologic staging. The operative ap-
proach was median sternotomy in 60% and antero-
lateral thoracotomy in 40%. At operation, 25 pa-
tients (58%) had mediastinal invasion involving the
pericardium (n 5 23), pleura (n 5 20), lung (n 5 8),
phrenic nerve (n 5 14), or innominate vessels (n 5
9). Final pathologic staging was performed by the
Masaoka staging system: stage I, encapsulated tu-
mor; stage II, invasion into surrounding fatty tissue
or mediastinal pleura or microscopic invasion of the
thymic capsule; stage III, invasion of mediastinal
structures (i.e., lung, pericardium, or great vessels);
stage IVa, metastasis confined to the intrathoracic
cavity; stage IVb, distant metastasis.4 There were
three patients with stage I disease (7%), 15 stage II
(35%), 20 stage III (47%), and 5 stage IVa (11%).
Of 43 thymic carcinomas, 16 tumors were well-
differentiated thymic carcinomas and 27 were type II
malignant thymomas.
Patient treatment. Overall, 29 patients (67%)
had complete resection and 14 patients had incom-
plete resection (33%). Of the 14 patients who had
incomplete resection, 5 had invasion of great arter-
ies, 1 had synchronous metastasis, 2 had chest wall
involvement, and 6 had extensive mediastinal inva-
sion. Patients having incomplete resection were
treated postoperatively with chemotherapy (n 5 l),
radiation (n 5 6), and combined chemotherapy and
radiation (n 5 7). Patients having complete resec-
tion received adjuvant chemotherapy (n 5 3), radi-
ation (n 5 8), and combined chemotherapy and
radiation (n 5 13).
Factors associated with survival of all patients
(n 5 43). Of 43 patients, overall survival was 65% at
5 years, and 35% at 10 years. Survival was not
dependent on age (p 5 0.13), sex (p 5 0.9), or tumor
size (p 5 0.89). Five-year survivals for patients
undergoing complete resection (n 5 29) and incom-
plete resection (n 5 14) were 68% and 62%, respec-
tively (p 5 0.18). Survival was not dependent on
Masaoka stage (p 5 0.29). There were three stage I
patients with survivals of 3.6, 4.1, and 8.2 years.
Median survivals of stage II patients (n 5 15), stage
III patients (n 5 20), and stage IV patients (n 5 6.7)
were 9.2, 5.3, and 6.7 years, respectively. Survival of
patients with early stage disease (stage I or II) as
defined by Masaoka classification was no different
from that of patients with advanced stage disease III
or IV (Fig. 1). Survival of patients with well-differ-
entiated thymic carcinomas was similar to that of
patients with type II malignant thymomas (Fig. 2).
Survival was adversely affected (p 5 0.009) by the
presence of tumor invasion of the innominate ves-
sels (vein and or artery). Patients with invasion of
the innominate vessels (n 5 9) had a 5-year survival
of 37% compared with a 75% 5-year survival for
patients (n 5 34) with no innominate vessel invasion
(Fig. 3). Survival of patients was not dependent on
tumor invasion of mediastinal structures with the
exception of the innominate vessels (Table I).
Fig. 1. Survival of patients with thymic carcinoma (n 5
43) stratified by Masaoka stage: early stage I, II (n 5 18)
versus advanced stage III, IV (n 5 25).
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Patterns of recurrence. Of 29 patients having
complete resection, median follow-up was 3.8 years.
There was a total of 16 recurrences, with 11 local
recurrences, 2 distant metastases, and 3 local with
distant metastases. Overall recurrence was 65% at 5
years and 75% at 10 years (Fig. 4). There were 12
actual long-term survivors (.4 years), with a median
survival of 6.7 years (range 4 to 14.2 years). Of these
long-term survivors, four patients had no evidence
of disease at 4.0, 4.1, 8.2, and 14.2 years, five patients
were alive with recurrent disease at 4.1, 6.3, 8.2,
10.1, and 12.9 years, and three patients were dead
from progression of disease at 4.4, 6.6, and 6.8 years.
Effect of clinicopathologic factors on recurrence.
Recurrence in patients having complete resection
was not dependent on age (p 5 0.94), sex (p 5 0.5),
presentation with symptoms (p 5 0.62), or tumor
size (p 5 0.42). No difference was found in recur-
rence in patients based on Masaoka stage (Fig. 5).
Recurrence in patients with innominate vessel inva-
sion (n 5 6) and with no vessel invasion (n 5 23)
were both 45% at 4 years. Patients with well-
differentiated thymic carcinomas had a recurrence
rate similar to patients with type II thymomas (Fig.
6).
Multivariable models. Survival of patients with
thymic carcinoma was dependent only on innomi-
nate vessel invasion (95% CI 1.3 to 15.8; p 5 0.02).
Extent of resection (complete vs incomplete; p 5
0.2), Masaoka stage (p 5 0.8), and microscopic
Fig. 2. Survival of patients with thymic carcinoma: well-
differentiated thymic carcinoma (n 5 16) compared with
type II malignant thymoma (n 5 27).
Fig. 3. Survival of patients with thymic carcinoma with
innominate vessel invasion (n 5 9) compared with no
vessel invasion (n 5 34).
Table I. Survival of patients’ (n 5 43) by site of
mediastinal invasion
Site Invasion Survival (5 yr) p Value
Pericardium No (n 5 20) 62%
Yes (n 5 23) 70% 0.31
Pleura No (n 5 23) 65%
Yes (n 5 20) 70% 0.2
Lung No (n 5 35) 65%
Yes (n 5 8) 62% 0.77
Phrenic nerve No (n 5 29) 70%
Yes (n 5 14) 55% 0.43
Innominate vessels No (n 5 34) 75%
Yes (n 5 9) 37% (4yr) 0.009
Fig. 4. Overall recurrence in patients having complete
resection for thymic carcinoma (n 5 29).
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 2
Blumberg et al. 3 0 5
subtype (well-differentiated vs type II thymoma; p 5
0.3) were not factors predictive of survival. Recur-
rence in patients with thymic carcinoma was not
dependent on Masaoka stage (p 5 0.4), innominate
vessel invasion (p 5 0.6), or microscopic subtype
(p 5 0.15).
Discussion
Until recently the diagnosis of thymic carcinoma
as a real clinical entity has been questioned and has
been a significant source of confusion for patholo-
gists and clinicians alike. All thymic carcinomas are
believed to arise from the epithelial cells of the
thymus. Thymic carcinomas or type lI malignant
thymomas, as originally defined by Rosai and Le-
vine, are epithelial thymic tumors with clear-cut
malignant cytologic features, including nucleolar
prominence, high nuclear/cytoplasm ratios, and
abundant mitoses. In addition, there are seven
unique histologic subtypes of thymic carcinoma,
including squamous, mucoepidermoid, basaloid,
sarcomatoid, small cell, lymphoepithelial, and clear
cell.9, 10 A second classification of epithelial tumors
of the thymus by Mu¨ller-Hermelink has further
complicated the diagnosis of this disease.11 This
classification scheme differentiates thymic carcino-
mas from thymic carcinomas on the basis of cortical
and medullary components, “organotypic differenti-
ation.” By this scheme, thymomas are classified as
medullary, cortical, or mixed type, whereas thymic
carcinomas show a loss of medullary and cortical
organization. Among the thymic carcinomas, a sub-
group of tumors with only small areas of organotypic
differentiation exists and are classified as well-differ-
entiated thymic carcinomas. Thymic carcinomas with
complete lack of cortical and medullary features are
analogous to the original thymic carcinoma or type II
malignant thymoma proposed by Rosai. In our study
of 43 thymic carcinomas, there were 16 well-differen-
tiated thymic carcinomas and 27 type II malignant
thymomas. By multivariate analysis, survival or recur-
rence was no different between these two subgroups of
thymic carcinomas. Although the diagnosis of thymic
carcinoma is clearly complicated for the pathologist,
treatment decision-making by the clinician need not
take into account the subtype of thymic carcinoma
because this variable does not seem to have a signifi-
cant impact on clinical outcome.
Patients with thymic carcinoma have been staged
by the same staging system used for thymoma, the
Masaoka classification. No studies, however, have
definitively validated the prognostic usefulness of
this classification for patients with thymic carci-
noma. Previous studies have demonstrated that pa-
tients with thymic carcinoma have a worse prognosis
compared with patients with thymomas; studies
examining prognostic factors unique to thymic car-
cinoma are sparse. Our objectives were to evaluate
the usefulness of Masaoka staging for patients with
thymic carcinoma and to determine unique prognos-
Fig. 5. Recurrence in patients having complete resection
for thymic carcinoma (n 5 29) stratified by Masaoka
stage: early stage I, II (n 5 13) versus advanced stage III,
IV (n 5 16).
Fig. 6. Recurrence in patients having complete resection
for thymic carcinoma (n 5 29): well-differentiated thymic
carcinoma (n 5 10) compared with type II malignant
thymoma (n 5 19).
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tic factors in a sizable cohort of patients compared
with other studies.
Prior studies have suggested that the poor out-
come of these patients is in part related to the
advanced stage (Masaoka) of patients at initial
presentation.4 Our data, however, refute this. In our
series, we were unable to confirm that stage as
defined by the Masaoka staging system for thymoma
was of prognostic usefulness. By actuarial analysis,
survival of the entire cohort of 43 patients was not
predicted by Masaoka stage. Masaoka stage was also
not predictive of survival or recurrence in patients
who had complete resection. Of 43 patients, there
were 17 actual long-term survivors (.4 years). Ap-
proximately one half of these patients (n 5 8) had
advanced-stage disease (stage I, n 5 2; stage II, n 5
7; stage III, n 5 5; and stage IV, n 5 3), indicating
that long-term survival may not be dependent on
Masaoka stage. Despite the lack of correlation
between Masaoka stage and survival for thymic
carcinomas, we have previously shown that Masaoka
stage was predictive of survival for patients with
thymoma.8 These differences between thymoma and
thymic carcinoma would seem to reflect a true
biologic difference in these two diseases and not a
result of a small sample size. We found that prog-
nosis for patients with thymic carcinoma was depen-
dent solely on tumor invasion of the innominate
vessels. Other sites of tumor invasion within the
mediastinum were not associated with a poor out-
come. This further illustrates the lack of usefulness
of Masaoka classification in thymic carcinoma be-
cause all patients with mediastinal invasion would be
classified as having advanced stage III disease.
Although patients with innominate vessel inva-
sion have a worse prognosis, patients with thymic
carcinoma in general have a high recurrence rate
and poor survival. In addition, of those few long-
term survivors, only a minority (4/17) were free of
disease at last follow-up. Clearly this raises the
question of whether patients with thymic carcinoma
should be primarily treated by surgery. A lack of
efficacy of complete surgical resection for these
patients is suggested by similar survival rates for
patients who had complete resection compared with
those who had incomplete resection. Other reports
have also failed to show an improved survival in
patients having complete versus incomplete resec-
tion.4
Clearly other therapeutic modalities should be
explored in these patients. Recent studies have
shown some encouraging results for the use of
chemotherapy in patients with thymic carcinoma. In
our series, most patients were treated with adjuvant
chemotherapy, the most common drugs being cis-
platin, doxorubicin (Adriamycin), and cyclophos-
phamide (Cytoxan). Unfortunately, analysis of the
effect of chemotherapy in our series was limited
because of a wide variability of drug regimens
administered. Chemotherapy has been used success-
fully by other investigators. In one study, five pa-
tients were treated with cisplatin-based regimens,
with three clinical responses and two patients having
a complete response.14 A complete pathologic re-
sponse was also observed in a report of one patient
with thymic carcinoma who showed no pathologic
evidence of tumor after chemotherapy with a regi-
men of cisplatin, vinblastine, bleomycin, and etopo-
side.15 This same patient had metastatic disease at
initial presentation and was noted to be disease free
5 years later. Thymic carcinoma has also been shown
to be somewhat radiosensitive, with an 86% overall
response rate and evidence of regrowth in only 17%
of responders in one study.16 Combined radiation
and chemotherapy with cisplatin, vindesine, and
cyclophosphamide was studied in five patients with
partially resected tumors with one patient disease
free at 5 years.17 A more recent prospective study
has also shown efficacy for cisplatin-based chemo-
therapy in patients with advanced thymoma.18
Thymic carcinoma comprises a group of thymic
tumors with high risk of recurrence and poor overall
survival. We were unable to demonstrate that cur-
rent staging of thymic carcinoma by Masaoka clas-
sification for thymoma is prognostically useful. We
have demonstrated that survival for patients with
thymic carcinoma is adversely affected by tumor
invasion of the innominate vessels. All patients with
this disease, however, are at significant risk for
recurrence and should be considered for novel
treatment approaches.
We gratefully appreciate Dr. Juan Rosai’s review of all
pathologic material. We also thank T. J. Yao of the
Department of Blostatistics at Memorial Hospital.
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Discussion
Dr. Paul A. Kirschner (New York, N.Y.). Dr. Blumberg
and his associates have questioned the validity of the
Masaoka staging system as applied to prognosis of thymic
carcinoma. My comments will deal with the choice of the
staging system and with the definition of thymic carci-
noma.
To begin with, Masaoka and associates1 in 1981 specif-
ically excluded thymic carcinoma from the Masaoka stag-
ing system, restricting their cases only to those tumors
with bland cytologic features, be they (1) noninvasive,
encapsulated tumors, so-called benign thymoma, or (2)
invasive tumors (“malignant thymoma”) with bland cyto-
logic findings, the latter being category I of Rosai. Inva-
siveness was the prognostic parameter for Masaoka, not
histologic findings.
More confusing has been the definition of the term
thymic carcinoma. Early on, it was applied to frankly
undifferentiated epithelial tumors that were relatively
infrequent (usually a single-digit percentage of thymic
tumors) and, parenthetically, rarely if ever associated with
myasthenia gravis or other autoimmune phenomena.
More recently, the term well-differentiated thymic carci-
noma was introduced as part of the Mu¨ller-Hermelink
“cortical/medullary” histologic reclassification of thymic
epithelial tumors in 1989,2 and this new group straddles
the category I cytologically blind of Rosai and the cyto-
logically malignant category II of Rosai. It undoubtedly
accounts for the astonishing number of cases in Dr.
Blumberg’s series, 43 cases, or 36% of his total thymic
tumor experience at Memorial.
When the Massachusetts General Hospital3, 4 reclassi-
fied their cases according to this classification, they also
came up with a very high percentage (28%), not quite the
same percentage but a very high one, using the term
well-differentiated thymic carcinoma.
Parenthetically, the term thymic carcinoma was not used
in previous Memorial papers reporting on their experi-
ence with thymoma.
Further evidence of this overliberal use of the term
thymic carcinoma is the high incidence of autoimmune
disease reported by Dr. Blumberg, which I derived from
his manuscript, 14 cases, or 33%, including 10 with
myasthenia gravis, an incidence not heretofore noted in
true thymic carcinoma. My question is, what was the
incidence of myasthenia gravis in the high-grade tumors
with innominate vessel invasion?
Shimosato5 of Japan, in an editorial in 1994, deplored
the lack of a standard WHO histologic classification of
thymic tumors, as is present in many other types of tumors
that we deal with, including lung tumors. He also sup-
ported a TNM staging system, the latter having already
been proposed by Yamakawa and associates6 in a paper in
which Masaoka was one of the coauthors in 1991 and
Tsuchiya and coworkers7 in 1994 to more properly stage
thymic carcinoma by including the N factor. My question
is, what was the incidence of lymph node metastasis in this
series of cases?
In the current paper, Dr. Blumberg has also demon-
strated the need for subclassifying thymic carcinoma by
degree of histologic differentiation and invasiveness to
explain the discrepancies in recurrence and survivals in
this widened spectrum of thymic carcinoma. These dis-
crepancies appear to be derived from the use of a staging
system that was never intended to include thymic carci-
noma in the first place and an overly broad interpretation
of the term thymic carcinoma proper. The true situation
will probably be a balance between histology and invasive-
ness to more accurately stage all thymic epithelial tumors.
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Dr. Willard A. Fry (Evanston, Ill.). I have three ques-
tions. First, were most of the cases operated by sternot-
omy or bilateral thoracotomy? Second, was a total
thymectomy performed? Third, do you recommend radio-
therapy in all cases of thymic carcinoma as a postoperative
adjuvant? If yes, do you add chemotherapy?
Dr. Larry R. Kaiser (Philadelphia, Pa.). Your series
goes back to the 1940s. How complete was your follow-
up?
Dr. Blumberg. I thank Dr. Kirschner for his poignant
comments and acknowledge that he is clearly a recognized
authority in this area.
In response to your question regarding the definition of
thymic carcinoma and the large experience of these
tumors we are reporting, I would like to make several
comments. We have previously reported our experience
with 118 patients with thymoma treated at Memorial
Hospital from 1949 to 1993. In this report, 43 tumors were
classified as thymic carcinoma. This study represents a
subset analysis with the objectives of defining prognostic
factors and determining the usefulness of Masaoka stag-
ing in thymic carcinoma. To define a thymic carcinoma,
we have used both the classifications of Rosai and Mu¨ller-
Hermelink. Thymic carcinomas had either clear-cut ma-
lignant cytologic features (type II malignant thymoma) or
were well-differentiated thymic carcinomas. Our incidence
of thymic carcinomas was 43 of 118 (36%), which is similar
to other published reports. Hsu reported a 10-year expe-
rience with thymic carcinomas in 1994 in this Journal. Of
75 patients with thymic tumors, 20 had thymic carcinomas,
representing a 36% incidence. As you note, after reclas-
sifying their cases, the Massachusetts General Hospital
group has also reported a relatively high incidence of
thymic carcinoma. So clearly we have not been over liberal
in our diagnosis of thymic carcinoma. We have, in fact,
used the two currently accepted classifications for diag-
nosing thymic carcinoma. Our study demonstrates that
survival and recurrence of patients with thymic carcinoma
is similar independent of the classification used for diag-
nosis of thymic carcinoma. Patients with well-differenti-
ated thymic carcinomas and type II malignant thymomas
had a similar poor prognosis. Clearly both classification
systems should be used to discriminate thymic carcinoma
from benign thymomas to appropriately manage patients
with this highly aggressive disease.
The high incidence of myasthenia gravis in our group of
thymic carcinomas is clearly related to inclusion of well-
differentiated thymic carcinomas in our series. Myasthenia
gravis occurred in 10 of 43 patients. Of these 10 patients
with myasthenia gravis, 9 had well-differentiated thymic
carcinomas. The association of myasthenia gravis with
thymic carcinoma has previously been described by Mu¨l-
ler-Hermelink.
Dr. Kirschner made the point that Masaoka staging was
never intended as a clinical staging system for thymic
carcinoma. Despite this fact, studies in the literature,
including the experience of Hsu (J Thorac Cardiovasc
Surg 1994;107:615-20) have staged patients with thymic
carcinoma by Masaoka classification. Because we have a
large experience with thymic carcinoma patients, all of
whom were clinically staged by Masaoka classification, we
had the unique opportunity to evaluate the usefulness of
Masaoka classification in this disease. Unlike in patients
with thymoma, Masaoka stage is not predictive of prog-
nosis. Use of Masaoka staging in thymic carcinoma should
be cautioned against because patients with early-stage
disease with no mediastinal invasion (Masaoka stages I
and II) do as poorly as patients with advanced stage
disease with mediastinal invasion or metastases (Masaoka
stages III and IV). As pointed out by Dr. Kirschner,
investigators from Japan have advocated a TNM classifi-
cation for this disease. We do not have specific data on the
incidence of mediastinal lymph node metastases but
strongly believe that all patients with thymic carcinoma
should be treated aggressively because they are all at high
risk for recurrence.
Regarding Dr. Fry’s question on operative techniques,
60% of patients were explored with median sternotomy
and 40% with thoracotomy. All patients underwent a total
thymectomy.
In regard to the use of adjuvant therapy, we recom-
mend a multimodality approach in all patients with
thymic carcinoma. As we have pointed out, there are
data in the literature to support the efficacy of chemo-
therapy and radiation in this disease. In our series most
patients received adjuvant therapy. Radiation was given
to 35 patients with a median dose of 5000 rad. Chemo-
therapy was administered to 24 patients. Cisplatin was
the most common agent. Most patients received a
combination of cisplatin, doxorubicin, and cyclophos-
phamide. We were unable to analyze the effect of
adjuvant treatment because there was no standard
adjuvant regimen. However the usefulness of adjuvant
therapy in our series is suggested by the 65% overall
5-year survival of patients, which is significantly higher
than other reported series.
In response to Dr. Kaiser: The median follow-up for the
entire cohort of 43 patients was 2.9 years and in the
completely resected group it was 3.8 years.
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